Pharmacy World and Science

, Volume 25, Issue 4, pp 152–155 | Cite as

Medicines containing pharmaceutical excipients with known effects: a French review

  • I. Fusier
  • C. Tollier
  • M.C. Husson


Objective: The 13/01/01 French decree published an official list of brands and their generic drugs and identified 38 groups of excipients with known effects which are responsible for side effects and contraindication respectively. Our objective was to review all medicines marketed in France containing these excipients and to disseminate this information to French health care practitioners.Method : The side effects and contraindications regarding these excipients have been documented in the French drug database Theriaque ( . They were documented for each medicine containing these excipients in addition to the data mentioned in the Summary of Product Characteristics ( SPC) . Results were obtained on 1 June 2001 by using computerised queries from the database. Results: Within the 38 groups, 300 specific excipients and derivatives with known effects were identified. Among the 8900 medicines ( 100% ) , 5567 medicines ( 62.6% ) contained one or more of these excipients; 2483 contained 1 excipient, 1819 contained 2 excipients and 1265 contained 3 or more excipients; 410 side effects or contra‐ indications – were described according to the route of administration and the threshold dose. They were linked to these 5567 medicines; 5818 excipients with a threshold dose were mentioned in the 'composition' sections of these 5567 medicines. Among these 5818 excipients, 3385 quantitative doses were documented in the SPCs or EPARs.Conclusion: This review shows the extent of most of the excipients contained in medicines marketed in France. The dissemination of these data offsets the lack of information in the SPCs.

Adverse effects Drug database Drug information France Generic drug Pharmaceutical excipient 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    De Jong HJ. The safety of pharmaceutical excipients. Therapie 1999; 54: 11–4.Google Scholar
  2. 2.
    Duneton P. Décision du 20 novembre 2000 portant inscription au répertoire des groupes géneriques mentionné à l'article R5143–8 du code de la santé publique. Official journal of the French Republic 2001; 51003–64.Google Scholar
  3. 3.
    Kibbe AH. Handbook of pharmaceutical excipients, 3rd ed, London: The Pharmaceutical Press, 2000.Google Scholar
  4. 4.
    Weiner M, Bernstein LI. Adverse reactions to drug formulation agents. New York: Marcel Dekker, 1989.Google Scholar
  5. 5.
    Sweetman SC. Martindale - the complete drug reference, 32nd ed. London: The Pharmaceutical Press, 1999.Google Scholar
  6. 6.
    Kennedy E, Moody M. An investigation of factors affecting community pharmacist's selection of over the counter preparations. Pharm World Sci 2000; 22(2): 47–52.Google Scholar
  7. 7.
    Krishnan HS, Schaefer M. Evaluation of the impact of pharmacist's advice giving on the outcomes of self-medications in patients suffering from dyspepsia. Pharm World Sci 2000; 22(3): 102–8.Google Scholar
  8. 8.
    Papa CM, Shelley WB, Menthol hypersensitivity. JAMA 1964; 189: 546–8.Google Scholar
  9. 9.
    Hayakawa R, Yamamura M, Sugiura M. Contact dermatitis from 1–menthol. Cosmet Toilet 1996; 117(7): 28–9.Google Scholar
  10. 10.
    Van Assendalft AHW. Bronchospasm induced by vanillin and lactose. Eur J Respir Dis 1984; 65: 468–72.Google Scholar
  11. 11.
    Academy of Pediatrics Committee on Drugs. ‘Inactive’ ingredients in pharmaceutical products: update (subject review). Pediatrics 1997; 99(2): 268–78.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • I. Fusier
    • 1
  • C. Tollier
    • 1
  • M.C. Husson
    • 1
  1. 1.CNHIM‐Hôpital de BicêtreCentre National Hospitalier d'Information sur le MédicamentLe Kremlin Bicêtre CedexFrance E‐mail

Personalised recommendations